# GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

> **NCT02243371** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 93 (actual)

## Conditions studied

- Previously Treated Metastatic Adenocarcinoma of the Pancreas

## Interventions

- **BIOLOGICAL:** CRS-207
- **BIOLOGICAL:** CRS-207
- **DRUG:** nivolumab
- **BIOLOGICAL:** GVAX
- **DRUG:** CY

## Key facts

- **NCT ID:** NCT02243371
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-02
- **Primary completion:** 2017-07-21
- **Final completion:** 2017-07-21
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2021-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243371, "GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02243371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*